33 patents
Page 2 of 2
Utility
RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
4 May 21
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Angiopoietin-like 3 (also called ANGPTL3, ANGPL3, angiopoietin-like protein 3) gene expression, and compositions that include ANGPTL3 RNAi agents.
Zhen Li, Rui Zhu, So Wong
Filed: 13 Sep 18
Utility
Compositions and methods for inhibiting gene expression of Hif2alpha
23 Feb 21
RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2α (EPAS1) gene are described.
So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
Filed: 16 Apr 18
Utility
Compositions and methods for inhibiting gene expression of factor XII
7 Dec 20
RNA interference (RNAi) triggers for inhibiting the expression of Factor XII (F12) gene through the mechanism of RNA interference are described.
Steven B. Kanner, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
Filed: 2 Jun 19
Utility
RNAi therapy for hepatitis B virus infection
19 Oct 20
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Christine I. Wooddell, David B. Rozema, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
Filed: 30 Sep 18
Utility
RNAi agents for Hepatitis B virus infection
21 Sep 20
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Zhen Li, Rui Zhu, Christine Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
Filed: 3 Aug 17
Utility
Compositions and methods for inhibiting gene expression of LPA
25 May 20
RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described.
Stacey Melquist, Steven Kanner, David B. Rozema, David L. Lewis, Lauren J. Almeida, Darren H. Wakefield, Vladimir S. Trubetskoy, Tao Pei, Zhen Li, Aaron Almeida
Filed: 20 Feb 18
Utility
Compositions and methods for inhibiting expression of RRM2 genes
13 Apr 20
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene.
John Frederick Boylan, Birgit Bramlage, Markus Hossbach, John Reidhaar-Olson
Filed: 26 Feb 18
Utility
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
23 Mar 20
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents.
Zhen Li, Rui Zhu, Tao Pei, Steven Kanner, So Wong
Filed: 9 Sep 18
Utility
RNAi agents for inhibiting expression of alpha-ENaC and methods of use
16 Mar 20
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an alpha-ENaC (SCNN1A) gene.
Zhen Li, Rui Zhu, Tao Pei, Anthony Nicholas, Erik W Bush
Filed: 4 Jul 18
Utility
Organic compositions to treat beta-ENaC-related diseases
3 Feb 20
The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
Antonin De Fougerolles, John Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
Filed: 19 Aug 18
Utility
RNAi inhibition of alpha-ENaC expression
27 Jan 20
The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
Filed: 17 Jan 18
Utility
Organic compositions to treat EPAS1-related diseases
20 Jan 20
The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic imflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.
Brian Bettencourt, Shanthi Ganesh, Elizabeth George, Dieter Huesken, Stuart Milstein, Jonathan Solomon, Emily Thomas, Ivanka Toudjarska, Jennifer Tullai, Jan Weiler
Filed: 6 Dec 17
Utility
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
21 Oct 19
RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described.
Zhen Li, Rui Zhu, Christine I. Wooddell, Tao Pei
Filed: 9 Jan 18